



**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

Applicant(s): **Martha A. Wild, et al.**

Application No.: **09/993,777**

Filed: **11/06/2001**

For: **RECOMBINANT  
LARYNGOTRACHEITIS VIRUS  
AND USES THEREOF**

: Group Art Unit: **1648**

: Examiner: **Zachariah Lucas**

: Attorney Docket No.: **SY01106KQ1**

X

**SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT**

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

(a) Pursuant to the duty of disclosure under 37 C.F.R. § 1.56, it is requested that the documents listed on the accompanying Form PTO-1449 be considered and made of record in the above-identified patent application. Copy(ies) of these documents ☒ are enclosed ☐ were filed in related U.S. Application No(s) \_\_\_\_\_ filed \_\_\_\_\_, respectively.

(b) No fee is believed to be due because:

- ☐ This Information Disclosure Statement is being submitted concurrently with the filing of the above-identified application; **or**
- ☐ This Information Disclosure Statement is being submitted within three (3) months of the filing date of the above-identified application; **or**
- ☐ This Information Disclosure Statement is being submitted concurrently with a Request for Continued Examination (RCE); **or**
- ☐ This Information Disclosure Statement is being submitted prior to the mailing of a first Office Action on the merits.

(c) ☒ This Information Disclosure Statement is being submitted before the mailing date of any final action, notice of allowance, or an action that otherwise closes prosecution; and:

- ☐ Each item of information contained in this Information Disclosure Statement was first cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement; **or**
- ☐ No item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the undersigned after making reasonable inquiry, no item of information contained in this Information Disclosure Statement was known to any individual designated in

§ 1.56(c), more than three months prior to the filing of this Information Disclosure Statement; **or**

☒ The Commissioner is hereby authorized to charge the requisite fee listed on the attached Fee Transmittal Sheet.

(d) ☐ This Information Disclosure Statement is being submitted on or before the payment of the issue fee; and:

☐ Each item of information contained in this Information Disclosure Statement was first cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement; **or**

☐ No item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the undersigned after making reasonable inquiry, no item of information contained in this Information Disclosure Statement was known to any individual designated in § 1.56(c), more than three months prior to the filing of this Information Disclosure Statement; **and**


☐ The Commissioner is hereby authorized to charge the requisite fee listed on the attached Fee Transmittal Sheet.

☒ The Commissioner is hereby authorized to charge any additional fees which may be required for this Information Disclosure Statement, or credit any overpayment to Deposit Account No. 19-0365. A DUPLICATE COPY OF THIS SHEET IS ENCLOSED.

Respectfully submitted,

Dated: January 15, 2003  
**Schering-Plough Corporation**  
Patent Department, K-6-1, 1990  
2000 Galloping Hill Road  
Kenilworth, NJ 07033-0530  
Facsimile No.: (908) 298-5388

By:



Name: Michael D. Davis  
Reg. No.: 39,161  
**Attorney of Record**  
Telephone No.: (908) 298-2194

Sheet 1 of 1

FORM PTO 149		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO.: <b>SY01106KQ1</b>		SERIAL NO.: <b>09/993,777</b>	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT  (Use several sheets if necessary)				APPLICANT: <b>Martha A. Wild, et al.</b>			
				FILING DATE: <b>11/06/2001</b>		GROUP: <b>1648</b>	
<b>U.S. PATENT DOCUMENTS</b>							
*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE IF APPROPRIATE
<b>FOREIGN PATENT DOCUMENTS</b>							
		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION YES NO
	DF	2,050,850	03/08/92	Canada			
	DG	WO 93/14194	07/22/93	PCT			
	DH	WO 95/03070	02/02/95	PCT			
<b>OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)</b>							
	DI	Johnson, M.A., et al., "Sequence characteristics of a gene in infectious laryngotracheitis virus homologous to glycoprotein D of herpes simplex virus," <i>The Journal of Sequencing and Mapping</i> 5:191-94 (1995)					
	DJ	Johnson, Michael A., et al., "Nucleotide sequence of infections laryngotracheitis virus (gallid herpesvirus 1) ICP4 gene," <i>Virus Research</i> 35:193-204 (1995)					
	DK	Johnson, Michael A., et al., "Molecular evolution of infectious laryngotracheitis virus (ILTV; gallid herpesvirus 1): An ancient example of the <i>Alphaherpesviridae</i> ?" <i>Veterinary Microbiology</i> 46:221-31 (1995)					
EXAMINER				DATE CONSIDERED			
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.							